Literature DB >> 27121751

5'-(E)-Vinylphosphonate: A Stable Phosphate Mimic Can Improve the RNAi Activity of siRNA-GalNAc Conjugates.

Rubina Parmar1, Jennifer L S Willoughby1, Jingxuan Liu1, Donald J Foster1, Benjamin Brigham1, Christopher S Theile1, Klaus Charisse1, Akin Akinc1, Erin Guidry2, Yi Pei2, Walter Strapps2, Mark Cancilla2, Matthew G Stanton2, Kallanthottathil G Rajeev1, Laura Sepp-Lorenzino1, Muthiah Manoharan1, Rachel Meyers1, Martin A Maier1, Vasant Jadhav3.   

Abstract

Small interfering RNA (siRNA)-mediated silencing requires siRNA loading into the RNA-induced silencing complex (RISC). Presence of 5'-phosphate (5'-P) is reported to be critical for efficient RISC loading of the antisense strand (AS) by anchoring it to the mid-domain of the Argonaute2 (Ago2) protein. Phosphorylation of exogenous duplex siRNAs is thought to be accomplished by cytosolic Clp1 kinase. However, although extensive chemical modifications are essential for siRNA-GalNAc conjugate activity, they can significantly impair Clp1 kinase activity. Here, we further elucidated the effect of 5'-P on the activity of siRNA-GalNAc conjugates. Our results demonstrate that a subset of sequences benefit from the presence of exogenous 5'-P. For those that do, incorporation of 5'-(E)-vinylphosphonate (5'-VP), a metabolically stable phosphate mimic, results in up to 20-fold improved in vitro potency and up to a threefold benefit in in vivo activity by promoting Ago2 loading and enhancing metabolic stability.
© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Clp1 kinase; RISC loading; oligonucleotides; phosphate mimic; siRNA

Mesh:

Substances:

Year:  2016        PMID: 27121751     DOI: 10.1002/cbic.201600130

Source DB:  PubMed          Journal:  Chembiochem        ISSN: 1439-4227            Impact factor:   3.164


  44 in total

Review 1.  Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug.

Authors:  Alexandre J Debacker; Jon Voutila; Matthew Catley; David Blakey; Nagy Habib
Journal:  Mol Ther       Date:  2020-06-17       Impact factor: 11.454

Review 2.  GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics.

Authors:  Aaron D Springer; Steven F Dowdy
Journal:  Nucleic Acid Ther       Date:  2018-05-24       Impact factor: 5.486

Review 3.  The chemical evolution of oligonucleotide therapies of clinical utility.

Authors:  Anastasia Khvorova; Jonathan K Watts
Journal:  Nat Biotechnol       Date:  2017-02-27       Impact factor: 54.908

4.  The valency of fatty acid conjugates impacts siRNA pharmacokinetics, distribution, and efficacy in vivo.

Authors:  Annabelle Biscans; Andrew Coles; Dimas Echeverria; Anastasia Khvorova
Journal:  J Control Release       Date:  2019-03-30       Impact factor: 9.776

Review 5.  Improving siRNA Delivery In Vivo Through Lipid Conjugation.

Authors:  Maire F Osborn; Anastasia Khvorova
Journal:  Nucleic Acid Ther       Date:  2018-05-10       Impact factor: 5.486

6.  Development of siRNA Therapeutics for the Treatment of Liver Diseases.

Authors:  Anja Holm; Marianne Bengtson Løvendorf; Sakari Kauppinen
Journal:  Methods Mol Biol       Date:  2021

7.  Gene Manipulation with Micro RNAs at Single-Human Cancer Cell.

Authors:  Andres Stucky; Xuelian Chen; Jiang F Zhong
Journal:  Methods Mol Biol       Date:  2018

8.  The Evolving Druggability and Developability Space: Chemically Modified New Modalities and Emerging Small Molecules.

Authors:  Wenzhan Yang; Prajakta Gadgil; Venkata R Krishnamurthy; Margaret Landis; Pankajini Mallick; Dipal Patel; Phenil J Patel; Darren L Reid; Manuel Sanchez-Felix
Journal:  AAPS J       Date:  2020-01-03       Impact factor: 4.009

Review 9.  RNA therapy: Are we using the right molecules?

Authors:  Ai-Ming Yu; Chao Jian; Allan H Yu; Mei-Juan Tu
Journal:  Pharmacol Ther       Date:  2018-12-04       Impact factor: 12.310

Review 10.  Genetic pharmacology: progresses in siRNA delivery and therapeutic applications.

Authors:  D Scherman; A Rousseau; P Bigey; V Escriou
Journal:  Gene Ther       Date:  2017-01-25       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.